INVENTIVA (EPA:IVA) | WebDisclosure

Basculer en Français

10161	Companies
208742	Keywords
138861	Articles
110649	Press releases

Home
Companies
INVENTIVA

PRESS RELEASE

published on 07/09/2025 at 22:05, 8 months 27 days ago

Inventiva names Jason Campagna as President of R&D and Chief Medical Officer and Martine Zimmermann as Executive Vice President of Regulatory Affairs and Quality Assurance
Inventiva appoints Jason Campagna as President of R&D and CMO and Martine Zimmermann as EVP of Regulatory Affairs and Quality Assurance, emphasizing long-term growth and operational excellence

Quality Assurance R&D Leadership Appointments Regulatory Affairs Inventiva
PRESS RELEASE

published on 07/09/2025 at 22:05, 8 months 27 days ago

Inventiva annonce la nomination de Jason Campagna en tant que Président de la R&D et Directeur Médical et de Martine Zimmermann en tant que Vice-Présidente Exécutive en charge des affaires réglementaires et de l’assurance qualité
Inventiva annonce la nomination de Jason Campagna en tant que Président de la R&D et Directeur Médical et de Martine Zimmermann en tant que Vice-Présidente Exécutive en charge des affaires réglementaires et de l’assurance qualité

Nomination R&D Affaires Réglementaires Inventiva Lanifibranor
BRIEF

published on 07/07/2025 at 22:05, 8 months 29 days ago

Inventiva Receives $10 Million Milestone Payment from CTTQ

Milestone Payment Lanifibranor Biopharmaceutical Development MASH Treatment CTTQ Partnership
BRIEF

published on 07/07/2025 at 22:05, 8 months 29 days ago

Inventiva reçoit un paiement d'étape de 10 millions de dollars du CTTQ

Paiement D'étape Lanifibranor Développement Biopharmaceutique Traitement MASH Partenariat CTTQ
PRESS RELEASE

published on 07/07/2025 at 22:00, 8 months 29 days ago

Inventiva receives $10 million milestone payment from CTTQ
Inventiva receives $10 million milestone payment from CTTQ following successful structured financing. Partnership aims to develop lanifibranor for MASH treatment in Chinese regions

Inventiva Milestone Payment MASH Lanifibranor CTTQ
PRESS RELEASE

published on 07/07/2025 at 22:00, 8 months 29 days ago

Inventiva receives $10 million milestone payment from CTTQ
Inventiva reçoit un paiement d'étape de 10 millions de dollars de la part de CTTQ pour le développement de thérapies contre la stéatohépatite. Accord de licence avec potentiel de 265 millions de dollars supplémentaires

Paiement Inventiva Stéatohépatite Thérapies CTTQ
BRIEF

published on 07/02/2025 at 22:05, 9 months 3 days ago

Inventiva Publishes Promising Results on Lanifibranor for Liver Disease

Phase 2b Study Liver Disease Lanifibranor MASH Treatment Journal Of Hepatology Reports
BRIEF

published on 07/02/2025 at 22:05, 9 months 3 days ago

Inventiva publie des résultats prometteurs sur le lanifibranor pour les maladies du foie

Étude De Phase 2b Maladie Du Foie Lanifibranor Traitement MASH Journal Des Rapports D'hépatologie
PRESS RELEASE

published on 07/02/2025 at 22:00, 9 months 3 days ago

Inventiva announces the publication in Journal of Hepatology Reports on results of lanifibranor treatment on liver sinusoidal endothelial cells in patients with MASLD/MASH and in preclinical models of the disease
Inventiva announces publication in Journal of Hepatology Reports on lanifibranor treatment effects on liver sinusoidal endothelial cells in MASLD/MASH patients and preclinical models, showing potential therapeutic benefits

Inventiva MASH Lanifibranor Journal Of Hepatology Reports LSEC Capillarization
PRESS RELEASE

published on 07/02/2025 at 22:00, 9 months 3 days ago

Inventiva annonce la publication dans le Journal of Hepatology Reports des résultats du lanifibranor sur les cellules endothéliales sinusoïdales hépatiques chez des patients MASLD/MASH et dans des modèles précliniques de la maladie
Inventiva annonce la publication des résultats du lanifibranor sur les cellules endothéliales sinusoïdales hépatiques chez des patients MASLD/MASH. Des effets bénéfiques allant au-delà de l'inversion de la capillarisation ont été observés

Inventiva MASH MASLD Lanifibranor Cellules Endothéliales

Accesswire

Published on 04/02/2026 at 22:00, 3 days 11 hours ago

Star Copper Announces Closing of Charity Flow-Through Unit Private Placement
Published on 04/02/2026 at 18:32, 3 days 14 hours ago

Datavault AI CEO Nathaniel Bradley to Present DataValue(R), DataScore(R), and Information Data Exchange(R) Technologies at XRP Tokyo 2026
Published on 04/02/2026 at 15:00, 3 days 18 hours ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress
Published on 04/02/2026 at 14:40, 3 days 18 hours ago

Northfield Capital Completes Acquisition Of Additional Interest In Juno Corp. And Announces Issuance Of Class B Multiple Voting Shares
Published on 04/02/2026 at 14:30, 3 days 18 hours ago

Worksport Announces COR(TM) Portable Energy System Is Now Fully Certified, Including Key UL and CSA Approvals, for North American Retail and Commercial Distribution

View all ACCESSWIRE

EQS Group

Published on 04/06/2026 at 09:05, 7 minutes ago

McDonald's Türkiye Launches Campaign Spotlighting Driving Safety
Published on 04/04/2026 at 10:07, 1 day 23 hours ago

Heidelberg Pharma to Present Data from its ADC Technology Platform at AACR Annual Meeting 2026
Published on 04/04/2026 at 02:05, 2 days 7 hours ago

Blokees made its debut at 2026 Thailand Toy Expo, exhibiting multiple products
Published on 04/03/2026 at 18:00, 2 days 15 hours ago

IEVA GROUP: IMPLEMENTATION OF A LIQUIDITY AGREEMENT WITH CREDIT INDUSTRIEL ET COMMERCIAL
Published on 04/03/2026 at 18:00, 2 days 15 hours ago

IEVA GROUP: MISE EN OEUVRE D’UN CONTRAT DE LIQUIDITE AVEC LE CREDIT INDUSTRIEL ET COMMERCIAL

Les Echos

Published on 04/03/2026 at 18:46, 2 days 14 hours ago

Disclosure of Share Capital and Voting Rights as of March 31, 2026
Published on 04/03/2026 at 18:46, 2 days 14 hours ago

Déclaration du nombre d’actions et droits de vote au 31 mars 2026
Published on 04/03/2026 at 18:01, 2 days 15 hours ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 2 days 15 hours ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 04/03/2026 at 18:00, 2 days 15 hours ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 mars 2026

View all LES ECHOS COMFI WIRE